Therapeutic antibodies

Submission status
Submission deadline

Since the approval of the first therapeutic monoclonal antibody in 1986, the development of antibody based treatments has grown rapidly to the point that they are now the predominant class of drugs undergoing clinical trial. Though the use of therapeutic antibodies has been particularly beneficial in the fields of oncology and haematology, they are an emerging treatment for a broad range of medical conditions. While a number of these drugs have proved successful there is potential for improvement of their activity in treatment through increasing bioavailabilty and affinity.

This Collection invites manuscripts describing the potential use of antibody based therapeutics and the development of associated methods that will facilitate improved delivery or drug discovery.

Submit manuscript
Submission guidelines
Manuscript editing services
Release of monoclonal antibodies, illustration - stock illustration


Articles will be displayed here once they are published.